Green Buckeye RN


Medscape: FDA Announces Phase Out of CFC-Based Asthma and COPD Inhalers
April 26, 2010, 10:05 am
Filed under: News

Emma Hitt, PhD
 
April 16, 2010 — In compliance with a rule about ozone-depleting substances, the US Food and Drug Administration (FDA) has announced that 7 available asthma and chronic obstructive pulmonary disease (COPD) metered-dose inhalers that use chlorofluorocarbons (CFCs) as propellants are being removed from the marketplace.

The phase out is to comply with the Montreal Protocol on Substances that Deplete the Ozone Layer. Alternative medications that contain hydrofluoroalkanes are available to substitute for the CFC-based products.

Affected Products

nedocromil (Tilade Inhaler, King Pharmaceuticals), June 14, 2010
metaproterenol (Alupent Inhalation Aerosol, Boehringer Ingelheim), June 14, 2010
triamcinolone (Azmacort Inhalation Aerosol, Abbott Laboratories), December 31, 2010
cromolyn (Intal Inhaler, King Pharmaceuticals), December 31, 2010
flunisolide (Aerobid Inhaler System, Forest Laboratories), June 30, 2011
albuterol and ipratropium in combination (Combivent Inhalation Aerosol, Boehringer Ingelheim Pharmaceuticals), December 31, 2013
pirbuterol (Maxair Autohaler, Graceway Pharmaceuticals), December 31, 2013

Read further at http://www.medscape.com/viewarticle/720397?sssdmh=dm1.612550&src=nldne&uac=76491MZ

Advertisements

Leave a Comment so far
Leave a comment



Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s



%d bloggers like this: